About Us
OVERVIEW
XOMA Ltd. (Nasdaq: XOMA) is a biotechnology company focused on the discovery, development and manufacturing of monoclonal antibody-based therapeutics for unmet medical needs.
XOMA’s world-class monoclonal antibody technologies have contributed to the development of marketed biologics with a total of more than $1 billion in annual sales and for which XOMA received substantial royalties. The company also has a strong track record of product discovery and development collaborations with pharmaceutical and biotechnology companies and the U.S. government, and has licensed certain of its fundamental technologies to numerous pharma and biotech companies.
XOMA’s objective is to develop and commercialize its products in the U.S. for markets that can be addressed with a targeted sales and marketing organization. The company’s flagship product is gevokizumab (XOMA 052), a humanized antibody to interleukin-1β (IL-1β) with potential for the treatment of the inflammatory cause of multiple diseases. XOMA also has a pipeline of product candidates directed primarily at metabolic and oncologic diseases, and a U.S. government-funded biodefense business.
Les Laboratoires Servier, France’s leading independent pharmaceutical company, is partnered with XOMA for gevokizumab development. This collaboration brings together Servier’s resources and expertise in pharmaceutical product development and commercialization with XOMA’s biologics clinical development and manufacturing capabilities.
Today, XOMA’s principal activities are centered on the advancement of gevokizumab, its preclinical pipeline and its biodefense business.
- Gevokizumab has been evaluated in Phase 1 and 2 clinical trials involving approximately 500 treated patients. In these trials, XOMA 052 was well-tolerated and demonstrated clinical activity in a seven-patient proof-of-concept study in vision-threatening Behçet’s uveitis, an orphan indication. Based on these results and available data from clinical evaluations of other IL-1 pathway-inhibiting biologics, XOMA believes that gevokizumab has considerable clinical and commercial potential which will be evaluated in a series of Phase 2 proof-of-concept trials. The first of these, in moderate to severe acne, is underway. Servier and XOMA plan to initiate Phase 3 development of gevokizumab for non-anterior, non-infectious uveitis including Behçet’s uveitis (NIU).
- XOMA’s preclinical pipeline of novel antibodies includes the XMetA and XMetS classes of antibodies that modulate the insulin receptor for the treatment of diabetes and metabolic syndrome, and programs targeting validated oncology targets.
- Antibodies against botulinum toxins, led by XOMA 3AB, a novel combination of three antibodies to prevent and treat botulism poisoning caused by exposure to botulinum neurotoxin Type A, among the most deadly bioterror threats. XOMA 3AB is in a Phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
- As a result of a previous collaboration between Novartis and XOMA, Novartis is developing HCD122, a monoclonal antibody to CD40 currently in Phase 1/2 clinical trials for the treatment of lymphoma, and LFA102, a monoclonal antibody to the prolactin receptor currently in a Phase 1 clinical trial for certain breast and prostate cancers.
XOMA is located in Berkeley, California.
